Related Experiment Videos
Vasopressin and malignant deoxycorticosterone hypertension in rats
Clinical Science and Molecular Medicine. Supplement
|December 1, 1976
Summary
Arginine-vasopressin significantly impacts malignant deoxycorticosterone (DOC) hypertension in rats. Blocking this hormone lowers blood pressure, suggesting its crucial role in this hypertension model.
Area of Science:
- Endocrinology
- Nephrology
- Cardiovascular Research
Background:
- Deoxycorticosterone (DOC) hypertension is a model for studying high blood pressure.
- The role of arginine-vasopressin (AVP) in severe hypertension is not fully understood.
Purpose of the Study:
- To investigate the role of arginine-vasopressin (AVP) in the pathogenesis of malignant deoxycorticosterone (DOC) hypertension in rats.
- To compare the effect of AVP antiserum with angiotensin II antiserum on blood pressure in DOC-hypertensive rats.
Main Methods:
- Rats were subjected to DOC hypertension, and plasma AVP concentrations were measured.
- Specific antibody serums for AVP and angiotensin II were injected into hypertensive rats.
- Blood pressure responses were monitored after antiserum administration.
Main Results:
- Plasma AVP concentrations increased more than tenfold in malignant DOC hypertension.
- AVP antiserum significantly lowered blood pressure in malignant DOC hypertension.
- Angiotensin II antiserum had no effect on blood pressure in this model.
- In benign DOC hypertension, AVP levels were elevated, and AVP antiserum caused a small blood pressure reduction.
Conclusions:
- Arginine-vasopressin plays a critical role in the pathogenesis of malignant DOC hypertension in rats.
- AVP may be as important as the renin-angiotensin system in malignant renal hypertension.
- Targeting AVP could be a therapeutic strategy for severe hypertension.